Agenus Inc. (NASDAQ:AGEN) Receives Average Rating of “Hold” from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have earned a consensus recommendation of “Hold” from the six ratings firms that are covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $10.00.

Separately, HC Wainwright reissued a “neutral” rating on shares of Agenus in a research report on Thursday, December 5th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. Point72 DIFC Ltd bought a new position in Agenus during the 2nd quarter worth $51,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Agenus during the second quarter worth about $106,000. EP Wealth Advisors LLC acquired a new stake in Agenus during the third quarter worth about $55,000. HighTower Advisors LLC increased its holdings in Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 7,530 shares during the period. Finally, Blair William & Co. IL acquired a new position in shares of Agenus in the 2nd quarter valued at approximately $441,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Stock Down 4.2 %

Shares of Agenus stock opened at $3.40 on Friday. Agenus has a 12-month low of $2.50 and a 12-month high of $19.69. The business’s 50 day moving average is $3.22 and its 200-day moving average is $5.83. The stock has a market cap of $79.76 million, a P/E ratio of -0.30 and a beta of 1.27.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.